To be clear it isn't an analyst contradicting the Adagio's scientist, it is two other labs claiming the drug has neutralising properties. There isn't a reason to assume those findings are false and the company's isn't, just because it is their drug.

It all takes some explaining and certainly doesn't feel right, but nevertheless someone's reputation is on the line. I would hope for a response from Adagio.

There is one outstanding question - why does the analyst know of these findings while the company doesn't? If the analyst could present this data, then so could have they at the same time. If they had done so perhaps the SP would be signifcantly higher.$Adagio Therapeutics(ADGI)$